Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

mTOR kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mTOR (39) Akt (6) Aminoacyl-tRNA Synthetase (1) AMPK (2) Apoptosis (15) ATM/ATR (2) Aurora Kinase (2) Autophagy (11) Bcl-2 Family (2) Bcr-Abl (1) c-Met/HGFR (1) Caspase (2) CDK (1) Cytochrome P450 (1) DNA-PK (3) EGFR (3) FAK (1) IKK (1) Integrin (1) Parasite (2) PARP (2) PDGFR (2) PI3K (23) Pim (2) PKA (2) PKC (2) Reactive Oxygen Species (2) ROR (1) SphK (1) Src (2) VEGFR (2)
By Research Areas:	Cancer (52) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: mTOR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16956

Onatasertib 2 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of *mTOR* kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-13328

Sapanisertib 35+ Cited Publications INK-128; MLN0128; TAK-228	mTOR Autophagy	Cancer
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent *mTOR1/2* inhibitor with an IC₅₀ of 1 nM for mTOR kinase.

HY-109633

PI3K-IN-18	mTOR PI3K	Cancer
PI3K-IN-18 (Compound 1) is a PI3K inhibitor, and can also effectively inhibit the homologous enzymemTOR. The IC₅₀ values of PI3K-IN-18 for mTOR and PI3K-α were 49 nM and 41 nM, respectively .

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-111373

RapaLink-1 5+ Cited Publications	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent *mTOR* inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-10372

PP121 3 Publications Verification	mTOR PDGFR VEGFR Src Apoptosis	Cancer
PP121 is a multi-targeted kinase inhibitor with IC₅₀s of 10, 60, 12, 14, 2 nM for *mTOR, DNK-PK, VEGFR2, Src, PDGFR*, respectively.

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-116191

WJD008	PI3K mTOR	Cancer
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and *mTOR* and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .

HY-161509

PT-88	mTOR	Cancer
PT-88 is a highly selective inhibitor of *mTOR* (Mammalian target of rapamycin) (IC₅₀=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of *mTOR* protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of *mTOR* in tumorigenesis and development, especially in the treatment of breast cancer .

HY-154910

CC214-1	mTOR	Cancer
CC214-1 is a potentially efficacious *mTOR* inhibitor that induces autophagy ,with an IC₅₀ is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of *mTOR* kinase biology. CC214-1 can be used for Glioblastoma study .

HY-10422

AZD-8055 45+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive *mTOR* kinase inhibitor with an IC₅₀ of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2 .

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, *PI3-kinase, PKB/Akt, and mTOR* signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

HY-16962

CC-115 2 Publications Verification	DNA-PK mTOR	Cancer
CC-115 is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.

HY-16962A

CC-115 hydrochloride 2 Publications Verification	DNA-PK mTOR	Cancer
CC-115 hydrochloride is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.

HY-117923

PF-06465603	mTOR PI3K	Cancer
PF-06465603 is a highly potent and selective ATP-competitive kinase inhibitor and a class 1 PI3K and mTOR inhibitor. PF-06465603 is a metabolite of PF-04691502 with a terminal carboxylic acid structure .

HY-10811

GNE-493	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR* inhibitor with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-13246

Apitolisib 10+ Cited Publications GDC-0980; GNE 390; RG 7422	PI3K mTOR Apoptosis	Cancer
Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and **mTOR kinase (TORC1*/2) inhibitor* with IC₅₀s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a K_i of 17 nM for *mTOR*.

HY-15174

Dactolisib Tosylate Maximum Cited Publications 56 Publications Verification BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and *mTOR* kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-N10754

Aschantin	mTOR Cytochrome P450	Infection Cardiovascular Disease Cancer
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca ²⁺-antagonistic, platelet activating factor-antagonistic, and chemopreventive activities. Aschantin is a *mTOR* kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the *AKT/mTOR/AMPK/p38* pathway in leukemic cells. Antitumor activity .

HY-50673

Dactolisib Maximum Cited Publications 56 Publications Verification BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and *mTOR* kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and *mTOR, respectively. Dactolisib (BEZ235) inhibits* both mTORC1 and mTORC2.

HY-10971

Alisertib 40+ Cited Publications MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the *AKT/mTOR/AMPK/p38* pathway in leukemic cells. Antitumor activity .

HY-10620

PI3K-IN-22	PI3K mTOR	Cancer
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC₅₀s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I PI3K and *mTOR* inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and *mTOR, respectively. SN32976 shows high selectivity among other 442 kinases*. SN32976 shows anticancer effects .

HY-10423

OSI-027 10+ Cited Publications ASP7486	mTOR Autophagy	Cancer
OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive *mTOR* kinase activity inhibitor with an IC₅₀ of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC₅₀s of 22 nM and 65 nM, respectively .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of *mTOR* at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-162143

SKI-349	SphK Akt mTOR	Cancer
SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .

HY-10044

WYE-132 5+ Cited Publications WYE-125132	mTOR Apoptosis	Cancer
WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific *mTOR* kinase inhibitor (IC₅₀: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-15901A

LGB321 monohydrochloride	Pim mTOR	Cancer
LGB321 monohydrochloride is a potent, selective, orally active and ATP competitive inhibitor of all three PIM kinases. LGB321 monohydrochloride inhibits proliferation, *mTOR*-C1 signaling and phosphorylation of BAD in a number of cell lines derived from diverse hematologic malignancies. LGB321 monohydrochloride can be used for the research of hematologic malignancies .

HY-126077

MTI-31 LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

HY-164460

AZD1897	Pim	Cancer
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC₅₀ values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the *mTOR* and MCL1 pathways .

HY-N1050

Zederone	mTOR	Cancer
Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells .

HY-124760

hSMG-1 inhibitor 11e	mTOR PI3K CDK	Cancer
hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC₅₀ of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC₅₀ of 45 nM), PI3Kα/γ (IC₅₀s of 61 nM and 92 nM) and CDK1/CDK2 (IC₅₀s of 32 μM and 7.1 μM) .

HY-144059

AKT-IN-9	Akt	Cancer
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .

HY-144060

AKT-IN-10	Akt	Cancer
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .

HY-158688

PI3Kδ-IN-21	PI3K	Inflammation/Immunology
PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC₅₀ of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model .

HY-15268

PP487	c-Met/HGFR PI3K DNA-PK mTOR Bcr-Abl Src VEGFR EGFR PDGFR	Cancer
PP487 is a dual inhibitor of tyrosine kinase/PI(3)Ks with IC₅₀ values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, *mTOR, Hck, Src, EGFR, EphB4, and PDGFR*, respectively. PP487 can be used for cancer research .

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR .

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective PI3Kα inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-W348485

WRX606	mTOR	Cancer
WRX606 is an inhibitor for mTOR complex 1 (mTORC1). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 S6K1 (IC₅₀=10 nM), and the phosphorylation of the eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC₅₀=0.27 μM) in MCF-7. WRX606 exhibits cytotoxicity to HepG2 with IC₅₀ of 17 nM. WRX606 exhibits antitumor efficacy in mouse models .

HY-139534

ARI-1	ROR Apoptosis	Cancer
ARI-1 is an inhibitor of *receptor tyrosine kinase-like orphan receptor* 1 (ROR1) inhibitor. ARI-1 effectively inhibits aberrant ROR1 expression, which is associated with the development of non-small cell lung cancer (NSCLC) and EGFR-TKI-induced drug resistance. ARI-1 binds to the extracellular Frizzled domain of ROR1 and regulates *PI3K/AKT/mTOR* signaling in a ROR1-dependent manner. ARI-1 potently inhibits NSCLC cell proliferation and migration and has antitumor activity in vivo ^{[1] ^.}

HY-164384

DFX117	PI3K Akt mTOR Apoptosis	Cancer
DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits *PI3K/Akt/mTOR* pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC₅₀s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective **mTOR kinase** inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .

HY-15346

Copanlisib 20+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 20+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-136765

PI3K-IN-11	PI3K	Cancer
PI3K-IN-11 (compound 13) is a PI3K inhibitor, which selectively inhibits PI3Kα, PI3Kβ, PI3K, and PI3Kδ (IC₅₀s=6.4, 13, 8, and 11 nM, respectively) over mTOR (IC₅₀=2.9 μM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 μg/mL. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.

HY-N0281

Daphnetin 3 Publications Verification 7,8-Dihydroxycoumarin	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite	Inflammation/Immunology Cancer
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1ß, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

616 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 616 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, *PI3-kinase, PKB/Akt, and mTOR* signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks